LRG1 and melanoma: We also report that the novel LRG1-targeting ADC liberates its cytotoxic payload, which is coupled to the antibody via a cleavable dipeptide linker, presumably upon being metabolised by appropriate proteases (e.g. cathepsin B) and increases survival when applied to a subcutaneous mouse melanoma tumour model.